RxDoctor Payments Data

Pradeep Parihar, MD

Family Medicine · Allen, TXNPI 1316033418

Payments from drug & device makers

$4,117in general payments, 2019–2025

Across 222 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$522
  • Lilly USA, LLC$510
  • Abbott$404
  • Boehringer Ingelheim$309
  • Novo Nordisk$284
  • Phathom Pharmaceuticals, Inc.$215
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,117 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,187
Medicare patients
76
Services billed
1,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$66,235
JanuviaSitagliptin Phosphate20$30,732
MounjaroTirzepatide25$29,665
FarxigaDapagliflozin Propanediol24$28,263
JardianceEmpagliflozin13$19,152
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$15,782
Atorvastatin Calcium124$1,278
Celecoxib12$926
Losartan Potassium77$892
Gabapentin41$830
Albuterol Sulfate HfaAlbuterol Sulfate17$775
Metoprolol Succinate49$751
Omeprazole54$672
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide24$617
Ibandronate Sodium19$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$284$66,23561 claims
MerckJanuvia$177$30,73220 claims
Lilly USA, LLCMounjaro$510$29,66525 claims
AstraZenecaFarxiga$522$28,26324 claims
Boehringer IngelheimJardiance$309$19,15213 claims
GSKTrelegy Ellipta$141$15,78211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Allen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →